Fig. 4.

ABT-263 selectively eliminates growth-arrested cancer cells through the induction of apoptosis in poorly immunogenic tumors with DIO. (A–P) Representative FACS histograms and quantification of (A, B) total and (C, D) C₁₂FDG⁺ TAMs, (E, F) total and (G, H) C₁₂FDG⁺ TANs, (I, J) total and (K, L) C₁₂FDG⁺ TAECs, or (M, N) total and (O, P) C₁₂FDG⁺ LLC cells in the TME. Percentages indicate proportion of tumor-associated TAMs, TANs, TAECs, or cancer cells to viable cells. Bar charts indicate the absolute number of cells from a given cell type per gram of tumor or the relative number of C₁₂FDG⁺ cells from a given cell type per gram of tumor. (Q) Representative histograms depicting the cell cycle state of LLC cells within the TME. (R) Cell cycle analysis by FACS, represented as fold change to DMSO control in cancer cells at either the G0/G1 phase, or the G2/M phases. Percentages indicate proportions of LLC cells in the G0/G1 or the G2/M phase to total LLC cells. (S) Schematic representation of the cell cycle arrest of a C₁₂FDG⁺ LLC cell in the G1 phase. FACS data represent ≥3 independent experiments with ≥5 biological replicates. Statistics: (B, D, F, H, J, L, N, P, R) Two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001; 95% CI. Outliers were determined with the ROUT method (Q = 1, 0%). Error bars represent mean ± SEM. Each n represents biological replicates.